OncoMatch/Clinical Trials/NCT04901234
Adaptive RadioTherapy for OroPharynx Cancer
Is NCT04901234 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for oropharynx cancer.
This is a phase II randomized trial, where patients with histologically proven squamous cell carcinoma of oropharynx that have primary tumor (T3 - T4) in place, treated with curative intent chemoradiation, will be randomized to systematic mid-treatment MRI-based radiotherapy adaptation vs. standard of care. The primary objective is to compare patient-rated dysphagia (as assessed by the MD Anderson Dysphagia Inventory composite score at 6 months post-treatment in patients undergoing routine mid-treatment MR-guided radiotherapy adaptation vs. in patients receiving the current standard of care.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: irradiation of the head and neck region
Exception: excluding superficial radiation therapy for non-melanomatous skin cancer
Previous irradiation of the head and neck (HNC) region, excluding superficial radiation therapy for non-melanomatous skin cancer
Cannot have received: surgery of the head and neck region
Exception: except for incisional or excisional biopsies
Previous surgery of the HNC region (except for incisional or excisional biopsies)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify